
REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

Petter Bjornstad, MD, is executive director of the UW Medicine Diabetes Institute, professor of pediatrics and medicine, and the Raisbeck Endowed Chair of Diabetes Research at the University of Washington.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.